164 related articles for article (PubMed ID: 12665715)
1. Antiretroviral therapy and declining AIDS mortality in New York City.
Messeri P; Lee G; Abramson DM; Aidala A; Chiasson MA; Jessop DJ
Med Care; 2003 Apr; 41(4):512-21. PubMed ID: 12665715
[TBL] [Abstract][Full Text] [Related]
2. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
Borrell C; Rodríguez-Sanz M; Pasarín MI; Brugal MT; García-de-Olalla P; Marí-Dell'Olmo M; Caylà J
Eur J Public Health; 2006 Dec; 16(6):601-8. PubMed ID: 16698886
[TBL] [Abstract][Full Text] [Related]
3. Universal decline in mortality in patients with advanced HIV-1 disease in various demographic subpopulations after the introduction of HAART in Hong Kong, from 1993 to 2002.
Chan KC; Wong KH; Lee SS
HIV Med; 2006 Apr; 7(3):186-92. PubMed ID: 16494633
[TBL] [Abstract][Full Text] [Related]
4. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
7. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
8. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
9. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
10. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
11. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
[TBL] [Abstract][Full Text] [Related]
12. Major reduction in AIDS-mortality inequalities after HAART: the importance of absolute differences in evaluating interventions.
Regidor E; Sánchez E; de la Fuente L; Luquero FJ; de Mateo S; Domínguez V
Soc Sci Med; 2009 Feb; 68(3):419-26. PubMed ID: 19056156
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
14. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
[TBL] [Abstract][Full Text] [Related]
15. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
16. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
17. Is it possible to reduce AIDS deaths without reinforcing socioeconomic inequalities in health?
Antunes JL; Waldman EA; Borrell C
Int J Epidemiol; 2005 Jun; 34(3):586-92. PubMed ID: 15737970
[TBL] [Abstract][Full Text] [Related]
18. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
19. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
20. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
